What is Royalty Pharma's retained earnings?

Royalty Pharma (RPRX) reported retained earnings of $2.51B in Q1 2026.

How has Royalty Pharma's retained earnings changed year-over-year?

Royalty Pharma's retained earnings increased by 1.1% year-over-year, from $2.48B to $2.51B.

What is the long-term trend for Royalty Pharma's retained earnings?

Over 5 years (2020 to 2025), Royalty Pharma's retained earnings has grown at a 4.2% compound annual growth rate (CAGR), from $1.92B to $2.36B.

What does retained earnings mean?

Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Royalty Pharma RPRX Retained Earnings

Retained Earnings at other companies

Ligand PharmaceuticalsLGND

$594.74M+30.3%

BridgeBio PharmaBBIO

-$3.99B-22.1%

Rigel PharmaceuticalsRIGL

-$1.01B+26.4%

Roivant SciencesROIV

-$501.81M-532%

ALN

Alnylam PharmaceuticalsALNY

-$6.33B+14.6%

Ionis PharmaceuticalsIONS

-$2.84B-24.9%

Other financials

Income statement

See full

Revenue$630.6M+11.0%

Operating income$563.0M+5.4%

Net income$294.7M+23.1%

EPS (diluted)$0.67+21.8%

Balance sheet

See full

Cash & equivalents$586.4M-46.1%

Total debt$9.0B+17.8%

Total equity$9.9B+1.6%

Total assets$19.8B+12.5%

Cash flow

See full

Operating cash flow$718.2M+20.5%

Valuation

See full

Market cap$26.58B+69.3%

Enterprise value$34.97B+51.4%

P/E32.1×+16.8×

P/S10.9×+4.1×

Profitability

See full

Operating margin65.1%-18.9pp

Net margin33.9%-14.4pp

Returns & leverage

See full

Return on equity8.4%-2.7pp

Debt / equity0.9×+0.1×

Current ratio2.7×+1.1×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Royalty Pharma's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Royalty Pharma's retained earnings?: Royalty Pharma (RPRX) reported retained earnings of $2.51B in Q1 2026.
How has Royalty Pharma's retained earnings changed year-over-year?: Royalty Pharma's retained earnings increased by 1.1% year-over-year, from $2.48B to $2.51B.
What is the long-term trend for Royalty Pharma's retained earnings?: Over 5 years (2020 to 2025), Royalty Pharma's retained earnings has grown at a 4.2% compound annual growth rate (CAGR), from $1.92B to $2.36B.
What does retained earnings mean?: Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.